Hisoar Pharmaceutical disclosed an earnings forecast, expecting a net loss attributable to the parent of 50 million to 75 million yuan in the first half of 2026, compared with a profit of 14.0937 million yuan in the same period last year. The net loss after deducting non-recurring items is expected to be 110 million to 135 million yuan, compared with a profit of 19.2833 million yuan in the same period last year. The company stated that the pharmaceutical segment incurred a loss due to continued losses in the penem series and declining gross margins for other products, along with asset impairment provisions. The dye segment saw growth in revenue and gross margin. Meanwhile, the depreciation of the US dollar against the renminbi had a significant negative impact on net profit. In addition, non-recurring gains and losses are expected to contribute approximately 60 million yuan, mainly from the increase in the valuation of indirectly held shares of Henlius and dividends from investee companies.
Shanghai Henlius Biotech IncHisoar's non-recurring gains include increased valuation of indirectly held shares of Henlius, implying Henlius's value rose.
Zhejiang Hisoar Pharmaceutical Co LtdHisoar expects a net loss of 50-75 million yuan in H1 2026, a sharp reversal from prior year profit, due to pharmaceutical losses and FX impact.